Bicycle Therapeutics plc (BCYC): Price and Financial Metrics
Bicycle Therapeutics plc (BCYC)
Today's Latest Price: $20.58 USD
Updated Dec 3 12:57pm
Add BCYC to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
See all "A" rated Strong Buy stocks
BCYC Stock Summary
- BICYCLE THERAPEUTICS plc's stock had its IPO on May 23, 2019, making it an older stock than just 2.42% of US equities in our set.
- With a price/sales ratio of 37.25, BICYCLE THERAPEUTICS plc has a higher such ratio than 94.49% of stocks in our set.
- With a year-over-year growth in debt of 964.41%, BICYCLE THERAPEUTICS plc's debt growth rate surpasses 97.99% of about US stocks.
- Stocks that are quantitatively similar to BCYC, based on their financial statements, market capitalization, and price volatility, are CDXS, DSPG, FPRX, FREQ, and NVCN.
- Visit BCYC's SEC page to see the company's official filings. To visit the company's web site, go to www.bicycletherapeutics.com.
BCYC Stock Price Chart Interactive Chart >
BCYC Price/Volume Stats
| Current price | $20.58 | 52-week high | $22.71 |
| Prev. close | $20.67 | 52-week low | $7.50 |
| Day low | $20.25 | Volume | 22,487 |
| Day high | $21.68 | Avg. volume | 47,179 |
| 50-day MA | $19.36 | Dividend yield | N/A |
| 200-day MA | $16.80 | Market Cap | 364.18M |
Bicycle Therapeutics plc (BCYC) Company Bio
Bicycle Therapeutics Plc is a holding company, which engages in the development of biopharmaceuticals. It focuses on developing a novel class of medicines, which the company refers to as bicycles, for diseases that are underserved by existing therapeutics. The firm utilizes its novel and proprietary phage display screening platform to identify bicycles. Its portfolio includes internal product candidates that are directed to oncology applications. The company was founded by Gregory Winter, John Tite, and Christian Heinis in 2009 and is headquartered in Cambridge, the United Kingdom.
Loading social stream, please wait...